Sabina Quader,\u00a0Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, Kawasaki, Kanagawa 210-0821 Japan<\/em><\/p>\n The brain is undoubtedly the body’s most essential and intricate organ, and brain disorders are closely tied to this intricacy. Categorized as \u00abCNS diseases,\u00bb a wide range of brain-related conditions – including Alzheimer’s, dementia, Amyotrophic Lateral Sclerosis, stroke, brain tumors, and more – present daunting challenges. Regrettably, many of these diseases currently lack adequate treatment, underscoring the urgent need for innovative and multidimensional efforts to combat these persistent problems. In this regard, nanomedicine shows tremendous potential for diagnosing and treating many life-threatening diseases, including cardiovascular and genetic disorders, CNS diseases, and cancers1<\/sup>. The field of nanomedicine is constantly revolutionizing healthcare with innovative approaches to tackling severe health issues. However, it is also crucial to actively translate these novel approaches more effectively. In our laboratory at the Innovation Center of NanoMedicine (iCONM), we aim to effectively bridge innovation and translation. Our nanomedicine platform is based on polymeric micelles that are constructed from poly(ethylene glycol)-b-poly(amino acids) (PEG-PAA) copolymers and have already demonstrated significant promise through their clinical translation potential2<\/sup>. The PEG-PAA copolymers are highly biocompatible and have the unique ability to engineer versatile, dynamic covalent chemistry-based approaches to link the cargo with the carriers; this feature ultimately improves spatiotemporal control over drug release kinetics, which is one of the critical properties of drug-loaded nanocarriers, along with size and surface properties. In this presentation, optimal design features of nanomedicine will be discussed, focusing on treating CNS diseases, mainly brain cancers3,4<\/sup>. An overview of our Japan-Spain international collaborative research focused on drug delivery to hypothalamic neurons for tackling obesity will also be presented5<\/sup>.<\/p>\n References<\/strong>–<\/p>\n Dr. Quader did her Ph.D. in Synthetic Organic Chemistry from Griffith University, Brisbane, Australia 2007. Following her Ph.D., she started working as a Research Chemist at Research Directions Pty Ltd, Brisbane, Australia. In 2010, she joined Professor Kazunori Kataoka’s world-renowned biomaterial research laboratory at the Materials Engineering Department of Tokyo University with a Japanese government -funded prestigious JSPS postdoctoral fellowship. After completing two years of JSPS fellowship, she continued her work at the same laboratory for another two years as Project Researcher. Since 2015, she has been an integral part of the Innovation Center of NanoMedicine (iCONM), Kawasaki, Japan, as a Senior Research Scientist and, as of 2023, as a Deputy Principal Research Scientist. Dr. Quader’s area of expertise lies in developing stimuli-sensitive nanomaterials tailored for targeted drug delivery to address challenging diseases. Dr. Quader is currently a principal investigator in multiple projects and overseeing international research activities at iCONM as Chief Coordinator of Global Partnership. One of her international collaborative research endeavors, \u00abCOnCorD,\u00bb was one of the three bilateral projects awarded by the Spanish State Agency for Research (AEI) and the Japanese Medical Research Agency (AMED) as a result of an invitation for joint project proposals from early-stage researchers in Japan and Spain in the \u00abNanomedicine\u00bb research area.<\/p>\n\n
\n
\n","protected":false},"excerpt":{"rendered":"